Alpha Cognition (ACOG) Q3 2026 earnings review
Alpha Cognition's sales rise 28%, but insurance coverage stays unchanged
Alpha Cognition sold far more of its Alzheimer's pill in nursing homes while its costs hardly moved. Sales of the drug, Zunveyl, climbed 28% from the second quarter, in step with bottles dispensed. Spending grew far more slowly, so the operating loss shrank. Chief executive Michael McFadden said this supports his goal of an operating profit in 2027.
| Zunveyl sales | $7.75M +28% from last quarter |
|---|---|
| Bottles dispensed | 10,896 +31% from last quarter |
| Operating loss | $6.4M $7.1M last quarter |
| Full-year cost outlook | Unchanged $50–54M for research, selling and overhead |
⚖️ Verdict: 🟢 Bullish
The story got better because demand kept growing after a strong second quarter. About three in four prescribers wrote repeat orders, so the growth comes from returning doctors as well as new ones. One caution: insurers have not yet widened access to the drug, the company said.
The question now is whether demand alone can carry Alpha Cognition to an operating profit. At this quarter's pace, sales would cover costs by mid-2027, by our math; if growth fades, the company may need more cash. The next results and the 2027 cost plan will tell.
🐂 Bull Case
Doctors Who Try Zunveyl Keep Prescribing It
Zunveyl is Alpha Cognition's only product, a pill for mild to moderate Alzheimer's disease that the company sells with a focus on nursing homes. Its growth depends on new doctors trying the drug and on those doctors writing it again.
Both measures improved in the third quarter, Alpha Cognition said. Pharmacies filled a record number of month-long bottles, and each prescribing doctor wrote at a faster rate than in the second quarter.
- Bottles dispensed: 10,896, up 31% from the second quarter
- Doctors prescribing in the quarter: 1,639, up 22%
- Doctors writing repeat orders: about 77%, from 76%
- Bottles per prescribing doctor: about 6.6, from 6.2
- Nursing homes with a prescription: 1,419, up 30%
Bottle growth eased from 37% in the second quarter. But it came from more doctors and heavier use together, so it does not depend on a few prescribers. Alpha Cognition lifted its goal for doctors who have ever prescribed, because it passed the old goal a quarter early.
What to watch: the fourth-quarter bottle count, due with the next results. Growth near this quarter's pace would show demand still compounding without help from insurers.
Sales Grew Four Times Faster Than Spending
Alpha Cognition still loses money, so its path to profit depends on sales outrunning costs. Chief executive Michael McFadden cited "disciplined operating spending" in the quarter, and the figures back him.
- Zunveyl sales: up 28% from the second quarter
- Spending on research, selling and overhead: up about 6%, by our math
- Selling, general and administrative costs, which pay for the sales force and head office: 159% of revenue, from 188%
Selling and overhead costs shrank as a share of sales because the sales team turned more visits into prescriptions. More than half of the doctors it visited went on to prescribe, against about 35% in the second quarter, Alpha Cognition said.
What to watch: fourth-quarter spending against the full-year cost plan, due with the next results. A figure close to the third quarter's would show costs still rising far more slowly than sales.
Nursing-Home Records Favor Zunveyl Over Generic Pills
Alpha Cognition describes Zunveyl as a drug "with expected minimal gastrointestinal side effects". In October it released first results from CONVERGE, a review of nursing-home medication records that tests whether patients on the drug reach a working dose.
- New patients at a working dose within six months: 79.1% on Zunveyl, 37.3% on generics
- All patients at a working dose: about 80% against about 54%
- Other medicines: Zunveyl patients dropped about twice as many types as they added
Nursing-home doctors can choose generic pills that cost less, so better dosing gives them a reason to pay for Zunveyl. But the company warned that the study "does not establish causality", since it did not adjust for differences between residents.
What to watch: the next CONVERGE updates, due in December and March, and a published paper in 2027. A paper would give the sales team evidence it can show doctors.
🐻 Bear Case
Insurance Deals Have Not Widened Access Yet
Alpha Cognition holds Medicare Part D contracts, the drug benefit for older Americans, with two large pharmacy benefit managers, the firms that run insurers' drug lists. The deals cover about 45 million people, but access opens only as individual plans put them into effect, the company said.
McFadden said real-world evidence and "improving payer access" position Zunveyl for growth. The same release said third-quarter growth came "without a meaningful change in formulary access", meaning the drug lists did not open further. Last quarter Alpha Cognition had said it expected that expansion to speed up in the second half.
This matters because, without plan coverage, doctors often need the insurer's approval before each prescription. Alpha Cognition's reimbursement team wins approval for about 95% of the cases it supports, so the gap slows growth rather than blocking it.
What to watch: the share of contracted plans that have added Zunveyl to their drug lists, a figure near 16% through June that the release did not update. A rise by year-end would make insurers a source of growth alongside new doctors.
Cash Must Last Until Sales Cover Costs
Alpha Cognition carries no debt but still loses money from operations, so its cash must last until sales cover costs. The company said its cash and future sales "can support its plan toward operating profitability in 2027".
- Cash at September 30: $37.8 million, from $41.4 million in June
- Proceeds from warrant and option exercises: about $1.4 million
- Cash used before those proceeds: about $5.0 million, by our math
The quarter argued against the funding worry, because the outflow ran well under the first half's pace. But a rise in unpaid bills helped, and those bills come due. By our math, sales must still nearly double to cover today's spending.
What to watch: year-end cash, due with the fourth-quarter results. A similar outflow would leave cash for well over a year, which reaches into 2027.
Promised Study and Approval Dates Slipped Again
Alpha Cognition is building a version of its drug that dissolves under the tongue, for patients who struggle to swallow. Its partner CMS Pharma is seeking approvals in Asia. Both programmes carry dates the company set earlier, and both moved.
- Under-the-tongue absorption study: start moved from mid-2026 to early 2027
- Asian approvals: two expected this year, now spread into 2027
- CONVERGE first results: due in the third quarter, out in October
None of these programmes earns money yet, so the delays leave this year's sales untouched. But the under-the-tongue version has slipped in almost every quarter since mid-2025, which makes other dates from management less reliable.
What to watch: whether the absorption study starts in the first quarter of 2027, as the November presentation now shows. A start on time would end the run of delays for this programme.
Risks this quarter didn't answer
Several standing risks got no clear reading from the third-quarter release and presentation. Each needs a figure missing from these documents or a decision Alpha Cognition has not yet made.
- How long patients stay on Zunveyl: still undisclosed; CONVERGE tracks dosing, not how long residents keep taking it
- Discounts to insurers and wholesalers: absent from the release; the quarterly filing will show them
- Cheap generic rivals: Zunveyl remains the only product, and no new pricing data appeared
- Sales outlook: still no revenue forecast, only a cost plan
- Wholesaler stock: sales and bottles moved together this quarter; the filing will show stock levels
- Finance team: Henry Du remains interim finance chief, and first-half costs changed without a stated reason
👓 Other Themes
First-Half Costs Now Lower Than First Reported
Alpha Cognition's nine-month figures put first-half operating spending at about $23.7 million, by our math. That is about $1.1 million below the figure it reported last quarter. All of the change sits in research and development, and the release gives no reason. The lower base trims the second-quarter loss, so the third-quarter improvement looks smaller than on the old numbers.
💲 Other KPIs
Net sales per month-long bottle dispensed slipped about 2% from the second quarter, by our math, after climbing through the first half of 2026. The figure moves with wholesaler stocking and insurer discounts, so a small dip leaves sales close to demand. The release does not break out the discounts.
Stock on hand barely changed from June while sales rose. By our math, inventory now equals about 83% of a quarter's Zunveyl sales, against about 106% in June. At the end of 2025 it stood at about twice a quarter's sales, so stock is no longer absorbing cash.
Money customers owe Alpha Cognition rose about 28% from June, in step with sales. By our math, receivables equal about 90% of a quarter's revenue, the same as in June, so collections have kept pace with growth.
The average diluted share count stood about 30% above a year ago, by our math, mostly because of the October 2025 share sale. Shares outstanding rose about 1% from June as holders exercised warrants and options. Warrants, options and share units would add more than a third to the share count if all were used, the presentation shows.
🔮 Guidance
Unchanged. The plan still caps this year's spending on research, selling and overhead at $50–54 million. By our math, the middle of the range leaves about $14.5 million for the fourth quarter. That would be about 6% above the third. Alpha Cognition already cut this range once, from $54–58 million, and spending so far keeps the year inside it.
Unchanged. McFadden still targets an operating profit in 2027, and the company said its cash and future sales can fund the path. By our math, sales must reach about $14.6 million a quarter to cover third-quarter spending. At this quarter's growth rate, that happens around mid-2027. Alpha Cognition has not said whether the goal means one quarter or the full year.
Raised. The company now aims to pass 2,500 doctors who have ever prescribed Zunveyl this year, up from about 2,000. It reached 2,410 at the end of September. By our math, the new goal needs only about 90 more doctors in the fourth quarter. Alpha Cognition added 502 in the third quarter, so the bar sits low.
Unchanged. RESOLVE, a trial of Zunveyl in Alzheimer's patients with behaviour problems, should still finish by mid-2027. The presentation shows 57 of 150 planned patients enrolled in early November. By our math, that leaves about 62% still to join. The trial would take the drug's evidence "into the outpatient setting", beyond nursing homes, the company said.
❓ Key Questions
How much did discounts to insurers cut Zunveyl's price?
Discounts set how much each new bottle earns. Net sales per bottle dipped this quarter, and the release gives no figure for the gap between list and net prices.
How many nursing-home patients stay on Zunveyl after a year?
Repeat prescribing shows that doctors return, not that patients stay. In a frail population, patients who stop treatment limit how far the base can grow, so persistence decides the long-run sales level.
When will more Part D plans add Zunveyl to their lists?
The contracts cover about 45 million people, but growth came without wider access this quarter. A date for broader plan coverage would show when insurers start adding to demand.
Why did the release lower first-half research costs?
The nine-month figures imply lower first-half research spending than Alpha Cognition first reported. A reason would show whether this was a correction, a reclassification or a one-time credit.
Does the 2027 profit goal mean one quarter or the year?
By our math, this quarter's pace reaches break-even around mid-2027. A full-year operating profit would need faster growth, so the definition decides how demanding the goal is.